- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Finder makes money from featured partners, but editorial opinions are our own.
Advertiser disclosure
Autolus Therapeutics is a biotechnology business based in the US. Autolus Therapeutics shares (AUTL) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.29 – a decrease of 8.03% over the previous week. Autolus Therapeutics employs 463 staff and has a trailing 12-month revenue of around $10.1 million.
Our top picks for where to buy Autolus Therapeutics stock
- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you fund a new account within 30 days
- Complimentary access to a financial planner
Probability of member receiving $1,000 is 0.028%
How to buy Autolus Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – AUTL. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Autolus Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Autolus Therapeutics stock price (NASDAQ: AUTL)
Use our graph to track the performance of AUTL stocks over time.Autolus Therapeutics shares at a glance
Information last updated 2024-12-18.
| Latest market close | $2.29 |
|---|---|
| 52-week range | $2.24 - $7.45 |
| 50-day moving average | $3.53 |
| 200-day moving average | $4.15 |
| Wall St. target price | $10.45 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.22 |
Is it a good time to buy Autolus Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Autolus Therapeutics price performance over time
Historical closes compared with the close of $2.24 from 2024-12-19
| 1 week (2024-12-13) | -10.04% |
|---|---|
| 1 month (2024-11-22) | -23.81% |
| 3 months (2024-09-20) | -39.95% |
| 6 months (2024-06-21) | -41.51% |
| 1 year (2023-12-21) | -60.28% |
|---|---|
| 2 years (2022-12-21) | 16.06% |
| 3 years (2021-12-21) | 5.42 |
| 5 years (2019-12-19) | 13.12 |
Autolus Therapeutics financials
| Revenue TTM | $10.1 million |
|---|---|
| Gross profit TTM | $-130,860,000 |
| Return on assets TTM | -21.61% |
| Return on equity TTM | -82.2% |
| Profit margin | 0% |
| Book value | $1.79 |
| Market Capitalization | $609.4 million |
TTM: trailing 12 months
Autolus Therapeutics share dividends
We're not expecting Autolus Therapeutics to pay a dividend over the next 12 months.
Autolus Therapeutics share price volatility
Over the last 12 months, Autolus Therapeutics's shares have ranged in value from as little as $2.24 up to $7.45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Autolus Therapeutics's is 2.039. This would suggest that Autolus Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Autolus Therapeutics overview
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom. .
Frequently asked questions
What percentage of Autolus Therapeutics is owned by insiders or institutions?Currently 18.088% of Autolus Therapeutics shares are held by insiders and 77.47% by institutions. How many people work for Autolus Therapeutics?
Latest data suggests 463 work at Autolus Therapeutics. When does the fiscal year end for Autolus Therapeutics?
Autolus Therapeutics's fiscal year ends in December. Where is Autolus Therapeutics based?
Autolus Therapeutics's address is: The Mediaworks, London, United Kingdom, W12 7FP What is Autolus Therapeutics's ISIN number?
Autolus Therapeutics's international securities identification number is: US05280R1005 What is Autolus Therapeutics's CUSIP number?
Autolus Therapeutics's Committee on Uniform Securities Identification Procedures number is: 05280R100
More resources on Finder
More guides on Finder
-
How to buy Merck-and-Company stock (MRK)
Steps to owning and managing MRK, with 24-hour and historical pricing before you buy.
-
How to buy Eli Lilly and Company stock (LLY)
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
-
How to buy Intuitive Surgical stock (ISRG)
Steps to owning and managing ISRG, with 24-hour and historical pricing before you buy.
-
How to buy Vertex Pharmaceuticals stock (VRTX)
Steps to owning and managing VRTX, with 24-hour and historical pricing before you buy.
-
How to buy McKesson Corporation stock (MCK)
Steps to owning and managing MCK, with 24-hour and historical pricing before you buy.
-
How to buy UnitedHealth Group Incorporated stock (UNH)
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
-
How to buy Amgen stock (AMGN)
Steps to owning and managing AMGN, with 24-hour and historical pricing before you buy.
-
How to buy Abbott Laboratories stock (ABT)
Steps to owning and managing ABT, with 24-hour and historical pricing before you buy.
-
How to buy Pfizer stock (PFE)
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
-
How to buy Johnson & Johnson stock (JNJ)
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.
Ask a question